Do analysts recommend SBTX or VERU?

Veru has a consensus target price of $24.50, suggesting a potential upside of 1,055.66%. Given Veru's stronger consensus rating and higher possible upside, analysts clearly believe Veru is more favorable than Silverback Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silverback Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Veru 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Is SBTX or VERU more profitable?

Silverback Therapeutics' return on equity of -29.62% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Silverback Therapeutics N/A -29.62% -28.20% Veru N/A -47.58% -35.83%

Which has better earnings and valuation, VERU or DERM?

Journey Medical has higher revenue and earnings than Veru. Journey Medical is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veru $16.89M 2.14 -$22.73M -$0.69 N/A Journey Medical $61.86M 2.04 -$11.43M -$0.22 N/A

Is VERU or DERM more profitable?

Veru has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Journey Medical -8.95% -20.23% -6.60%

Does the media prefer VERU or DERM?

In the previous week, Journey Medical had 2 more articles in the media than Veru. MarketBeat recorded 3 mentions for Journey Medical and 1 mentions for Veru. Veru's average media sentiment score of 0.34 beat Journey Medical's score of -0.30 indicating that Veru is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Journey Medical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Do analysts prefer MENS or VERU?

Veru has a consensus price target of $24.50, indicating a potential upside of 1,055.66%. Given Veru's stronger consensus rating and higher possible upside, analysts plainly believe Veru is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Veru 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50

Which has stronger valuation and earnings, MENS or VERU?

Jyong Biotech has higher earnings, but lower revenue than Veru. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Veru $16.89M 2.14 -$22.73M -$0.69 N/A

Is MENS or VERU more profitable?

Jyong Biotech's return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Veru N/A -47.58% -35.83%

Which has higher earnings & valuation, VERU or ANTX?

Veru has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veru $16.89M 2.14 -$22.73M -$0.69 N/A Anthem N/A N/A -$35.17M -$1.07 N/A

Is VERU or ANTX more profitable?

Veru's return on equity of -47.58% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Anthem N/A -53.52% -48.63%

Does the media refer more to VERU or ANTX?

In the previous week, Anthem had 2 more articles in the media than Veru. MarketBeat recorded 3 mentions for Anthem and 1 mentions for Veru. Anthem's average media sentiment score of 0.94 beat Veru's score of 0.34 indicating that Anthem is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anthem 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VERU or CRDL more profitable?

Veru's return on equity of -47.58% beat Cardiol Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Cardiol Therapeutics N/A -180.44% -140.28%

Does the media refer more to VERU or CRDL?

In the previous week, Cardiol Therapeutics had 1 more articles in the media than Veru. MarketBeat recorded 2 mentions for Cardiol Therapeutics and 1 mentions for Veru. Veru's average media sentiment score of 0.34 beat Cardiol Therapeutics' score of 0.00 indicating that Veru is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiol Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Veru (VERU) Competitors

$2.12 +0.06 (+2.91%)

Closing price 11/6/2026 04:00 PM Eastern

Extended Trading

$2.13 +0.01 (+0.47%)

As of 11/6/2026 07:30 PM Eastern

Compare

VERU vs. SBTX, DERM, MENS, ANTX, and CRDL

Should you buy Veru stock or one of its competitors? Veru's main competitors and comparable companies include Silverback Therapeutics (SBTX), Journey Medical (DERM), Jyong Biotech (MENS), Anthem (ANTX), and Cardiol Therapeutics (CRDL). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Veru compare to Silverback Therapeutics?

Silverback Therapeutics (NASDAQ:SBTX) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, media sentiment, analyst recommendations, institutional ownership, risk and valuation.

Veru has higher revenue and earnings than Silverback Therapeutics. Veru is trading at a lower price-to-earnings ratio than Silverback Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Silverback Therapeutics	N/A	N/A	-$89.48M	-$2.42	N/A
Veru	$16.89M	2.14	-$22.73M	-$0.69	N/A

Silverback Therapeutics' return on equity of -29.62% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Silverback Therapeutics	N/A	-29.62%	-28.20%
Veru	N/A	-47.58%	-35.83%

In the previous week, Veru had 1 more articles in the media than Silverback Therapeutics. MarketBeat recorded 1 mentions for Veru and 0 mentions for Silverback Therapeutics. Veru's average media sentiment score of 0.34 beat Silverback Therapeutics' score of 0.00 indicating that Veru is being referred to more favorably in the news media.

Company	Overall Sentiment
Silverback Therapeutics	Neutral
Veru	Neutral

Silverback Therapeutics has a beta of 0.6, indicating that its stock price is 40% less volatile than the broader market. Comparatively, Veru has a beta of -1.2, indicating that its stock price is 220% less volatile than the broader market.

74.9% of Silverback Therapeutics shares are held by institutional investors. Comparatively, 47.2% of Veru shares are held by institutional investors. 34.4% of Silverback Therapeutics shares are held by insiders. Comparatively, 14.2% of Veru shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Veru has a consensus target price of $24.50, suggesting a potential upside of 1,055.66%. Given Veru's stronger consensus rating and higher possible upside, analysts clearly believe Veru is more favorable than Silverback Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Silverback Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Summary

Veru beats Silverback Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Veru compare to Journey Medical?

Veru (NASDAQ:VERU) and Journey Medical (NASDAQ:DERM) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

Journey Medical has higher revenue and earnings than Veru. Journey Medical is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.14	-$22.73M	-$0.69	N/A
Journey Medical	$61.86M	2.04	-$11.43M	-$0.22	N/A

Veru has a net margin of 0.00% compared to Journey Medical's net margin of -8.95%. Journey Medical's return on equity of -20.23% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Journey Medical	-8.95%	-20.23%	-6.60%

Veru has a beta of -1.2, suggesting that its stock price is 220% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market.

In the previous week, Journey Medical had 2 more articles in the media than Veru. MarketBeat recorded 3 mentions for Journey Medical and 1 mentions for Veru. Veru's average media sentiment score of 0.34 beat Journey Medical's score of -0.30 indicating that Veru is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Journey Medical	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Veru currently has a consensus target price of $24.50, indicating a potential upside of 1,055.66%. Journey Medical has a consensus target price of $14.00, indicating a potential upside of 213.20%. Given Veru's stronger consensus rating and higher possible upside, equities research analysts plainly believe Veru is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Journey Medical	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

47.2% of Veru shares are held by institutional investors. Comparatively, 7.3% of Journey Medical shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 14.5% of Journey Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Veru and Journey Medical tied by winning 8 of the 16 factors compared between the two stocks.

How does Veru compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, valuation and risk.

47.2% of Veru shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Jyong Biotech's return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Veru	N/A	-47.58%	-35.83%

In the previous week, Veru had 1 more articles in the media than Jyong Biotech. MarketBeat recorded 1 mentions for Veru and 0 mentions for Jyong Biotech. Veru's average media sentiment score of 0.34 beat Jyong Biotech's score of 0.00 indicating that Veru is being referred to more favorably in the news media.

Company	Overall Sentiment
Jyong Biotech	Neutral
Veru	Neutral

Jyong Biotech has higher earnings, but lower revenue than Veru.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Veru	$16.89M	2.14	-$22.73M	-$0.69	N/A

Veru has a consensus price target of $24.50, indicating a potential upside of 1,055.66%. Given Veru's stronger consensus rating and higher possible upside, analysts plainly believe Veru is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Jyong Biotech has a beta of 2.52, indicating that its share price is 152% more volatile than the broader market. Comparatively, Veru has a beta of -1.2, indicating that its share price is 220% less volatile than the broader market.

Summary

Veru beats Jyong Biotech on 8 of the 12 factors compared between the two stocks.

How does Veru compare to Anthem?

Veru (NASDAQ:VERU) and Anthem (NASDAQ:ANTX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Veru has higher revenue and earnings than Anthem. Anthem is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.14	-$22.73M	-$0.69	N/A
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A

Veru has a beta of -1.2, meaning that its share price is 220% less volatile than the broader market. Comparatively, Anthem has a beta of -0.93, meaning that its share price is 193% less volatile than the broader market.

47.2% of Veru shares are owned by institutional investors. Comparatively, 90.5% of Anthem shares are owned by institutional investors. 14.2% of Veru shares are owned by insiders. Comparatively, 22.6% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Veru's return on equity of -47.58% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Anthem	N/A	-53.52%	-48.63%

Veru currently has a consensus price target of $24.50, suggesting a potential upside of 1,055.66%. Anthem has a consensus price target of $9.00, suggesting a potential upside of 125.00%. Given Veru's stronger consensus rating and higher possible upside, research analysts plainly believe Veru is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Anthem had 2 more articles in the media than Veru. MarketBeat recorded 3 mentions for Anthem and 1 mentions for Veru. Anthem's average media sentiment score of 0.94 beat Veru's score of 0.34 indicating that Anthem is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anthem	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Veru beats Anthem on 9 of the 14 factors compared between the two stocks.

How does Veru compare to Cardiol Therapeutics?

Veru (NASDAQ:VERU) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

In the previous week, Cardiol Therapeutics had 1 more articles in the media than Veru. MarketBeat recorded 2 mentions for Cardiol Therapeutics and 1 mentions for Veru. Veru's average media sentiment score of 0.34 beat Cardiol Therapeutics' score of 0.00 indicating that Veru is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cardiol Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veru has a beta of -1.2, meaning that its stock price is 220% less volatile than the broader market. Comparatively, Cardiol Therapeutics has a beta of 1.03, meaning that its stock price is 3% more volatile than the broader market.

Veru presently has a consensus target price of $24.50, suggesting a potential upside of 1,055.66%. Cardiol Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 905.03%. Given Veru's higher possible upside, research analysts clearly believe Veru is more favorable than Cardiol Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Cardiol Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Veru has higher revenue and earnings than Cardiol Therapeutics. Cardiol Therapeutics is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.14	-$22.73M	-$0.69	N/A
Cardiol Therapeutics	N/A	N/A	-$24.20M	-$0.25	N/A

47.2% of Veru shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Veru's return on equity of -47.58% beat Cardiol Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Cardiol Therapeutics	N/A	-180.44%	-140.28%

Summary

Veru beats Cardiol Therapeutics on 9 of the 12 factors compared between the two stocks.

Get Veru News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERU vs. The Competition

Export

Metric	Veru	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$36.15M	$13.28B	$7.76B	$11.80B
Dividend Yield	N/A	2.59%	2.47%	4.59%
P/E Ratio	-3.07	30.10	34.49	30.58
Price / Sales	2.14	6.48	8.23	5.55
Price / Cash	N/A	15.55	21.82	22.30
Price / Book	1.70	5.07	4.53	3.82
Net Income	-$22.73M	$2.85B	$3.51B	$382.47M
7 Day Performance	-3.20%	-1.60%	-1.01%	-2.27%
1 Month Performance	-12.40%	-6.44%	-4.45%	-7.57%
1 Year Performance	-17.19%	-5.51%	2.63%	-6.75%

Veru Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERU Veru	2.7522 of 5 stars	$2.12 +2.9%	$24.50 +1,055.7%	-17.2%	$36.15M	$16.89M	N/A	20	News Coverage Analyst Downgrade
SBTX Silverback Therapeutics	N/A	$4.03 -6.7%	N/A	-66.0%	$145.31M	N/A	N/A	83	High Trading Volume
DERM Journey Medical	1.8114 of 5 stars	$4.97 -1.0%	$14.00 +181.7%	-50.9%	$141.68M	$68.18M	N/A	58	Upcoming Earnings
MENS Jyong Biotech	N/A	$1.77 flat	N/A	-95.4%	$134.57M	N/A	N/A	27
ANTX Anthem	2.2811 of 5 stars	$3.63 +2.3%	$9.00 +147.9%	+250.6%	$133.96M	N/A	N/A	N/A	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERU) was last updated on 11/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veru (VERU) Competitors

VERU vs. SBTX, DERM, MENS, ANTX, and CRDL

How does Veru compare to Silverback Therapeutics?

Summary

How does Veru compare to Journey Medical?

Summary

How does Veru compare to Jyong Biotech?

Summary

How does Veru compare to Anthem?

Summary

How does Veru compare to Cardiol Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU vs. The Competition

Veru Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veru (VERU) Competitors

VERU vs. SBTX, DERM, MENS, ANTX, and CRDL

How does Veru compare to Silverback Therapeutics?

Which has better earnings and valuation, SBTX or VERU?

Is SBTX or VERU more profitable?

Does the media favor SBTX or VERU?

Which has more volatility and risk, SBTX or VERU?

Do insiders and institutionals have more ownership in SBTX or VERU?

Do analysts recommend SBTX or VERU?

Summary

How does Veru compare to Journey Medical?

Which has better earnings and valuation, VERU or DERM?

Is VERU or DERM more profitable?

Which has more volatility & risk, VERU or DERM?

Does the media prefer VERU or DERM?

Do analysts recommend VERU or DERM?

Do insiders & institutionals have more ownership in VERU or DERM?

Summary

How does Veru compare to Jyong Biotech?

Do insiders and institutionals believe in MENS or VERU?

Is MENS or VERU more profitable?

Does the media favor MENS or VERU?

Which has stronger valuation and earnings, MENS or VERU?

Do analysts prefer MENS or VERU?

Which has more risk and volatility, MENS or VERU?

Summary

How does Veru compare to Anthem?

Which has higher earnings & valuation, VERU or ANTX?

Which has more volatility & risk, VERU or ANTX?

Do insiders and institutionals hold more shares of VERU or ANTX?

Is VERU or ANTX more profitable?

Do analysts rate VERU or ANTX?

Does the media refer more to VERU or ANTX?

Summary

How does Veru compare to Cardiol Therapeutics?

Does the media refer more to VERU or CRDL?

Which has more risk and volatility, VERU or CRDL?

Do analysts rate VERU or CRDL?

Which has preferable valuation & earnings, VERU or CRDL?

Do insiders & institutionals hold more shares of VERU or CRDL?

Is VERU or CRDL more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU vs. The Competition

Veru Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools